420 related articles for article (PubMed ID: 21330577)
41. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values.
Jin GZ; Dong H; Yu WL; Li Y; Lu XY; Yu H; Xian ZH; Dong W; Liu YK; Cong WM; Wu MC
BMC Cancer; 2013 Mar; 13():161. PubMed ID: 23537217
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma.
Gao L; Antic T; Hyjek E; Gong C; Mueller J; Waxman I; DeMay RM; Reeves W
Cancer Cytopathol; 2013 Nov; 121(11):644-52. PubMed ID: 23674382
[TBL] [Abstract][Full Text] [Related]
43. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma.
Sakamoto M; Mori T; Masugi Y; Effendi K; Rie I; Du W
Intervirology; 2008; 51 Suppl 1():42-5. PubMed ID: 18544947
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.
Yao S; Zhang J; Chen H; Sheng Y; Zhang X; Liu Z; Zhang C
J Histochem Cytochem; 2013 Sep; 61(9):639-48. PubMed ID: 23686365
[TBL] [Abstract][Full Text] [Related]
45. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
46. High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.
Findeis-Hosey JJ; Huang J; Li F; Yang Q; McMahon LA; Xu H
Hum Pathol; 2011 Jun; 42(6):867-72. PubMed ID: 21292308
[TBL] [Abstract][Full Text] [Related]
47. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis.
Kim H; Choi GH; Na DC; Ahn EY; Kim GI; Lee JE; Cho JY; Yoo JE; Choi JS; Park YN
Hepatology; 2011 Nov; 54(5):1707-17. PubMed ID: 22045674
[TBL] [Abstract][Full Text] [Related]
48. Expression of HNF-1 alpha and HNF-1 beta in various histological differentiations of hepatocellular carcinoma.
Wang W; Hayashi Y; Ninomiya T; Ohta K; Nakabayashi H; Tamaoki T; Itoh H
J Pathol; 1998 Mar; 184(3):272-8. PubMed ID: 9614379
[TBL] [Abstract][Full Text] [Related]
49. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis.
Roskams T; Kojiro M
Semin Liver Dis; 2010 Feb; 30(1):17-25. PubMed ID: 20175030
[TBL] [Abstract][Full Text] [Related]
50. Histone-modifying genes as biomarkers in hepatocellular carcinoma.
Hung SY; Lin HH; Yeh KT; Chang JG
Int J Clin Exp Pathol; 2014; 7(5):2496-507. PubMed ID: 24966962
[TBL] [Abstract][Full Text] [Related]
51. Atypical large well-differentiated hepatocellular carcinoma with benign nature: a new clinical entity.
Kudo M
Intervirology; 2004; 47(3-5):227-37. PubMed ID: 15383732
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
53. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
54. Probability of hepatocellular carcinoma of small hepatocellular nodules undetectable by computed tomography during arterial portography.
Tanaka Y; Sasaki Y; Katayama K; Hiramatsu N; Ito A; Murata H; Enomoto N; Oshita M; Mochizuki K; Tsujii M; Tsuji S; Kasahara A; Tomoda K; Nakamura H; Hayashi N; Hori M
Hepatology; 2000 Apr; 31(4):890-8. PubMed ID: 10733545
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic value of clusterin immunostaining in hepatocellular carcinoma.
Li Y; Liu F; Zhou W; Zhang S; Chu P; Lin F; Wang HL
Diagn Pathol; 2020 Oct; 15(1):127. PubMed ID: 33054843
[TBL] [Abstract][Full Text] [Related]
56. Hypoxia-induced NIPP1 activation enhances metastatic potential and predicts poor prognosis in hepatocellular carcinoma.
Huang Y; Tao Y; Hu K; Lin F; Li X; Feng T; Wang ZM
Tumour Biol; 2016 Nov; 37(11):14903-14914. PubMed ID: 27644248
[TBL] [Abstract][Full Text] [Related]
57. Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules.
Luo Q; Zhang Y; Wang N; Jin G; Jin H; Gu D; Tao X; Huo X; Ge T; Cong W; Wang C; Qin W
Oncotarget; 2015 Mar; 6(9):6989-99. PubMed ID: 25749520
[TBL] [Abstract][Full Text] [Related]
58. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques.
Shafizadeh N; Kakar S
Adv Anat Pathol; 2011 Nov; 18(6):438-45. PubMed ID: 21993269
[TBL] [Abstract][Full Text] [Related]
59. High-b-value diffusion-weighted MR imaging of hepatocellular lesions: estimation of grade of malignancy of hepatocellular carcinoma.
Muhi A; Ichikawa T; Motosugi U; Sano K; Matsuda M; Kitamura T; Nakazawa T; Araki T
J Magn Reson Imaging; 2009 Nov; 30(5):1005-11. PubMed ID: 19856432
[TBL] [Abstract][Full Text] [Related]
60. Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma.
Nguyen TB; Roncalli M; Di Tommaso L; Kakar S
Mod Pathol; 2016 Mar; 29(3):283-92. PubMed ID: 26769138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
